

Financial news for AEZS dated on 2020-06-08: Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement

Financial news for AEZS dated on 2020-06-04: Aeterna Zentaris Announced That It Received A Positive Decision From The Listing Qualification Department Of Nasdaq

Financial news for AEZS dated on 2020-05-07: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2020-05-06: AEterna Zentaris Q1 EPS \$0.040 Up From \$(0.300) YoY, Sales \$1.100M Up From \$37.000K YoY

Financial news for AEZS dated on 2020-04-16: The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant

Financial news for AEZS dated on 2020-04-15: Aeterna Zentaris Reports Receives Nasdaq Notice Of Non Compliance Related To \$1/Share Minimum Bid Price Requirement; Co. Has Til Oct. 5, 2020 To Regain Compliance

Financial news for AEZS dated on 2020-04-06: Aeterna Zentaris Highlights Results In Dose-Finding Pediatric Study Of Macimorelin, Sees Planned Safety, Efficacy Study P02 Beginning Q4'20

Financial news for AEZS dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for AEZS dated on 2020-03-10: The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index

Financial news for AEZS dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for AEZS dated on 2020-02-20: 22 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2020-02-20: The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study

Financial news for AEZS dated on 2020-02-20: Aeterna Zentaris Announces \$4.5M Registered Direct Offering Priced At-The-Market; ~3.4M Shares Pirced @\$1.29375/Share

Financial news for AEZS dated on 2020-01-28: Aeterna Zentaris Reports Completion Of Patient Recruitment In Dose-Finding Pediatric Study Of Macimorelin

Financial news for AEZS dated on 2020-01-27: Aeterna Zentaris Regains Compliance With Nasdaq Minimum Bid Price Requirement For Continued Listing

Financial news for AEZS dated on 2020-01-23: 146 Biotechnology Stocks Moving In Thursday's Session

Financial news for AEZS dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for AEZS dated on 2020-01-10: 64 Biggest Movers From Yesterday

Financial news for AEZS dated on 2020-01-09: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for AEZS dated on 2020-01-09: The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, DBV Announces Positive Peanut Allergy Study Findings, Applied Genetic Soars On Trial Results

Financial news for AEZS dated on 2020-01-09: 20 Stocks Moving in Thursday's Pre-Market Session

Financial news for AEZS dated on 2020-01-08: Aeterna Zentaris shares are trading lower after the company received a Nasdaq notice regarding the minimum bid price requirement.

Financial news for AEZS dated on 2020-01-08: Aeterna Zentaris Receives NASDAQ Notification Regarding Minimum Bid Price Requirement

Financial news for AEZS dated on 2019-12-18: The Daily Biotech Pulse: Positive Adcom Verdict For Merck, Homology Medicine Slips On Mixed Gene Therapy Efficacy Data

Financial news for AEZS dated on 2019-12-17: The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail,

Dynavax Names CEO

Financial news for AEZS dated on 2019-12-16: Stocks That Hit 52-Week Lows On Monday

Financial news for AEZS dated on 2019-12-13: The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer

Financial news for AEZS dated on 2019-12-12: The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win

Financial news for AEZS dated on 2019-12-10: The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy \$3M In ContraFect Shares

Financial news for AEZS dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for AEZS dated on 2019-10-09: The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

Financial news for AEZS dated on 2019-10-08: Stocks That Hit 52-Week Lows On Tuesday

Financial news for AEZS dated on 2019-10-04: Aeterna Zentaris Announces Appointment of New President and Chief Executive Officer

Financial news for AEZS dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for AEZS dated on 2019-09-25: The Daily Biotech Pulse: PhaseBio Leaps On Trial Results, Pacira Set To Join SmallCap 600 Index, Positive Readout For Amgen's Blood Cancer Drug

Financial news for AEZS dated on 2019-09-24: The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger

Financial news for AEZS dated on 2019-09-20: Aeterna Zentaris Prices \$5M Registered Direct Offering At \$1.50/Unit

Financial news for AEZS dated on 2019-08-30: 70 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-08-15: 61 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-08-14: 48 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AEZS dated on 2019-08-13: AEterna Zentaris shares are trading higher after the company reported Q2 EPS and sales up from last year.

Financial news for AEZS dated on 2019-08-13: AEterna Zentaris Q2 EPS \$0.01 Up From \$(0.16) YoY, Sales \$194K Up From \$168K YoY

Financial news for AEZS dated on 2019-08-07: 85 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-08-06: 68 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AEZS dated on 2019-06-17: 46 Biggest Movers From Friday

Financial news for AEZS dated on 2019-06-14: 54 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-06-13: 38 Stocks Moving In Thursday's Mid-Day Session

Financial news for AEZS dated on 2019-06-10: 60 Biggest Movers From Friday

Financial news for AEZS dated on 2019-06-07: 44 Stocks Moving In Friday's Mid-Day Session

Financial news for AEZS dated on 2019-06-07: 55 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-06-06: Aeterna Zentaris Announces Workforce Reduction

Financial news for AEZS dated on 2019-05-09: 95 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-05-08: 75 Stocks Moving In Wednesday's Mid-Day

Session

Financial news for AEZS dated on 2019-05-08: 33 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEZS dated on 2019-05-07: AEterna Zentaris Q1 EPS \$(0.3) Down From \$0.87 YoY, Sales \$37K Down From \$24.658M YoY

Financial news for AEZS dated on 2019-04-12: 50 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-04-05: The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

Financial news for AEZS dated on 2019-04-03: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEZS dated on 2019-04-02: The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

Financial news for AEZS dated on 2019-04-01: 62 Biggest Movers From Friday

Financial news for AEZS dated on 2019-03-26: AEterna Zentaris Q4 EPS \$(0.31) Misses \$(0.19) Estimate

Financial news for AEZS dated on 2019-03-26: Earnings Scheduled For March 26, 2019

Financial news for AEZS dated on 2019-03-13: The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

Financial news for AEZS dated on 2019-03-12: Aeterna Zentaris Shares To Resume Trade At 5:00 p.m. EDT

Financial news for AEZS dated on 2019-03-12: Aeterna Zentaris Announces Strategic Review And Engagement Of Financial Advisor; Alternatives Include A Sale Of The Company And Opportunities For The License Of Macimorelin Outside Of The United States And Canada

Financial news for AEZS dated on 2019-03-12: AEterna Zentaris Shares Halted, News Pending

Financial news for AEZS dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for AEZS dated on 2019-01-17: 58 Biggest Movers From Yesterday

Financial news for AEZS dated on 2019-01-16: Aeterna Zentaris Reports Received European Marketing Clearance For Macimorelin

Financial news for AEZS dated on 2019-01-11: '\$AEZS Aeterna Zentaris receives European Commission Approval for Macimorelin for diagnosis of adult growth hormone deficiency.' -Tweet From TradeHawk

Financial news for AEZS dated on 2018-12-21: Aeterna Zentaris Settles Dispute With David, Dodd, Philip Theodore, Co. To Pay Dodd \$775K

Financial news for AEZS dated on 2018-12-04: Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018

Financial news for AEZS dated on 2018-12-04: The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO

Financial news for AEZS dated on 2018-12-04: 56 Biggest Movers From Yesterday

Financial news for AEZS dated on 2018-11-19: Aeterna Zentaris Receives Positive European Medicines Agency Opinion Of Macimorelin For Diagnosis of Adult Growth Hormone Deficiency

Financial news for AEZS dated on 2018-11-19: 55 Biggest Movers From Friday

Financial news for AEZS dated on 2018-11-16: Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Nov. 16, 2018

Financial news for AEZS dated on 2018-11-07: AEterna Zentaris Late Tuesday Reported Q3 EPS \$(0.15) Up From \$(0.61) YoY, Sales \$663K Up From \$241K YoY

Financial news for AEZS dated on 2018-11-06: Aeterna Zentaris Settles Dispute With Cogas Consulting, Co. Agrees To Pay \$625K; Contractual Relationship Between Companies Is Now Terminated

Financial news for AEZS dated on 2018-11-01: 56 Stocks Moving In Thursday's Mid-Day Session

Financial news for AEZS dated on 2018-11-01: Aeterna Zentaris Announces Novo Nordisk Acquires Rights to Macrilen in the United States and Canada, Terms Not Disclosed

Financial news for AEZS dated on 2018-11-01: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2018-10-31: Why AEterna Zentaris Shares Surged On Novo Nordisk-Strongbridge Biopharma Deal

Financial news for AEZS dated on 2018-10-31: AEterna Zentaris shares are up 63.9% following a deal between Novo Nordisk and Stonebridge for the rights to MACRILEN; AEterna Zentaris will receive 15%-18% royalties from the sale of MACRILEN rights.

Financial news for AEZS dated on 2018-10-31: Aeterna Zentaris Shares Up 25% Following Deal Between Novo Nordisk, Strongbridge For Rights To MACRILEN; Aeterna Zentaris Receives 15-18% Royalties From Sales Of MACRILEN In US, Canada

Financial news for AEZS dated on 2018-09-25: Aeterna Zentaris Appoints Leslie Auld As Chief Financial Officer

Financial news for AEZS dated on 2018-08-09: AEterna Zentaris Q2 EPS \$(0.16) Beats \$(0.32) Estimate, Sales \$168K Miss \$2M Estimate

Financial news for AEZS dated on 2018-06-21: 30 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2018-06-15: Maxim Group Terminates AEterna Zentaris

Financial news for AEZS dated on 2018-06-01: 58 Biggest Movers From Yesterday

Financial news for AEZS dated on 2018-05-30: 42 Biggest Movers From Yesterday

Financial news for AEZS dated on 2018-05-29: 37 Stocks Moving In Tuesday's Mid-Day Session

Financial news for AEZS dated on 2018-05-08: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AEZS dated on 2018-05-08: Benzinga's Daily Biotech Pulse: Valeant Earnings, Lipocine's FDA Watch, Invivo CFO Departure

Financial news for AEZS dated on 2018-05-07: Aeterna Zentaris Shares Up 9.0% After Hours Following Q1 Beat

Financial news for AEZS dated on 2018-05-07: AEterna Zentaris Q1 EPS \$0.88 Beats \$(0.31) Estimate, Sales \$24.6M Beat \$130K Estimate

Financial news for AEZS dated on 2018-03-28: Aeterna Zentaris Q4 EPS \$(0.03) vs \$(0.71) In Same Qtr. Last Year, Sales \$100K Misses \$130K Est.

Financial news for AEZS dated on 2018-03-27: Earnings Scheduled For March 27, 2018

Financial news for AEZS dated on 2018-03-13: Advaxis Shares Down 16.3% After Co. Announced Monday a Clinical Hold In Axalimogene Filolislac Phase 1/2 Combination Study With AstraZeneca's IMFINZI

Financial news for AEZS dated on 2018-03-05: Aeterna Zentaris Names James Clavijo CFO

Financial news for AEZS dated on 2018-03-05: Aeterna Zentaris Comments on the Class Action Lawsuit Related to Macrilen, Says Cannot Predict Expenses so Not Adding a Liability

Financial news for AEZS dated on 2018-01-18: 44 Biggest Movers From Yesterday

Financial news for AEZS dated on 2018-01-17: Mid-Afternoon Market Update: NeuroMetrix Climbs Following Announcement Of Collaboration With GlaxoSmithKline; Aerohive Networks Shares Drop

Financial news for AEZS dated on 2018-01-17: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for AEZS dated on 2018-01-17: Mid-Day Market Update: Dow Surges Over 150 Points; HTG Molecular Diagnostics Shares Plunge

Financial news for AEZS dated on 2018-01-17: Aeterna Zentaris Shares Up 19.32% After News Of Licensing Deal With Stonebridge Pharma

Financial news for AEZS dated on 2018-01-17: Mid-Morning Market Update: Markets Open Higher; Goldman Sachs Beats Q4 Expectations

Financial news for AEZS dated on 2018-01-17: 30 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEZS dated on 2018-01-17: Aeterna Zentaris Shares Resume, Stock Up 49%

Financial news for AEZS dated on 2018-01-17: Aeterna Zentaris Shares To Resume Trade At 7:30 a.m. EST

Financial news for AEZS dated on 2018-01-17: UPDATE: Aeterna Zentaris Says Will Receive 1-Time Milestone Payment Of \$5M From Stonebridge For FDA Approval Of Pediatric Indication For Macrilen

Financial news for AEZS dated on 2018-01-17: UPDATE: Aeterna Zentaris Will Receive Scheduled Of 1-Time Payments From Stonebridge Following Achievement Of 5 Commercial Milestone Events

Financial news for AEZS dated on 2018-01-17: UPDATE: Aeterna Zentaris Says Following End Of Patent Protection For Macrilen, Co. Will Be Entitled To 5% Royalty On Net Sales

Financial news for AEZS dated on 2018-01-17: UPDATE: Aeterna Zentaris Will Receive Upfront Payment Of \$24M From Stonebridge; As Long As Macrilen Is Patent Protected, Co. Will Be Entitled To 15% Royalty On Net Sales Up To \$75M, 18% Above \$75M

Financial news for AEZS dated on 2018-01-17: UPDATE: Zeterna Zentaris, Stonebridge Pharma Will Carry Out Development, Manufacturing, Registration, Commercialization Of Macrilen In US, Canada

Financial news for AEZS dated on 2018-01-17: Aeterna Zentaris Reports Entered Into Licensing Deal With Strongbridge For Macrilen In US, Canada

Financial news for AEZS dated on 2018-01-17: Aeterna Zentaris Shares Halted News Pending

Financial news for AEZS dated on 2017-12-26: 44 Biggest Movers From Friday

Financial news for AEZS dated on 2017-12-22: Aeterna Zentaris Offers Update On Litigation Against David Dodd, Philip Theodore: Counterclaim Alleges Defamatory Statements Related To Dodd, Theodore Were Made In Co. Press Release, Claims Damages Of \$6M

Financial news for AEZS dated on 2017-12-22: 36 Stocks Moving In Friday's Mid-Day Session

Financial news for AEZS dated on 2017-12-22: Mid-Day Market Update: Ignyta Surges Following Merger Deal With Roche; Agile Therapeutics Shares Plunge

Financial news for AEZS dated on 2017-12-22: 38 Biggest Movers From Yesterday

Financial news for AEZS dated on 2017-12-21: Mid-Afternoon Market Update: Aeterna Zentaris Climbs Following FDA Approval Of Macrilen; Apogee Shares Slide

Financial news for AEZS dated on 2017-12-21: 36 Stocks Moving In Thursday's Mid-Day Session

Financial news for AEZS dated on 2017-12-21: Mid-Day Market Update: Dow Surges Over 100 Points; PG&E Shares Plunge

Financial news for AEZS dated on 2017-12-21: Mid-Morning Market Update: Markets Open Higher; Conagra Tops Q2 Expectations

Financial news for AEZS dated on 2017-12-21: 35 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2017-12-21: A Peek Into The Markets: U.S. Stock Futures Up Ahead Of Economic Data

Financial news for AEZS dated on 2017-12-21: 10 Stocks To Watch For December 21, 2017

Financial news for AEZS dated on 2017-12-21: Aeterna Zentaris Shares Rise 74% to \$3.50 Following Wednesday Announcement FDA Approval of Macrilen for Diagnosis of Adult Growth Hormone Deficiency

Financial news for AEZS dated on 2017-12-20: Aeterna Zentaris Shares Resume, Spike

Higher, Now Up 48.6%

Financial news for AEZS dated on 2017-12-20: Aeterna Zentaris Shares To Resume Trade At 5:30 p.m. EST

Financial news for AEZS dated on 2017-12-20: Aeterna Zentaris Reports FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency

Financial news for AEZS dated on 2017-12-20: Aeterna Zentaris Shares Halted News Pending

Financial news for AEZS dated on 2017-12-08: Aeterna Zentaris Reports Departure of Interim CFO Jeffrey Whitnell Effective Immediately

Financial news for AEZS dated on 2017-11-30: Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Financial news for AEZS dated on 2017-11-28: Aeterna Zentaris Shares Up 1.5% Just After Open Following News Mon. Afternoon The Co.'s Macrilen Hormone Treatment Was Accepted For Marketing By the EMA

Financial news for AEZS dated on 2017-11-27: Aeterna Zentaris Announces EMA Has Accepted Marketing Authorization Application For Macrilen

Financial news for AEZS dated on 2017-11-08: Aeterna Zentaris Reports Q3 EPS \$(0.61) vs \$(0.26) Est., Sales \$241k vs \$120K Est.

Financial news for AEZS dated on 2017-09-25: Aeterna Zentaris Names Jeffrey Whitnell Interim CFO

Financial news for AEZS dated on 2017-09-01: Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer Genevieve Lemaire

Financial news for AEZS dated on 2017-08-08: Aeterna Zentaris Shares Resume Trade, Now Up 6% Following News Co. Has Engaged Advisors

Financial news for AEZS dated on 2017-08-03: Aeterna Zentaris Commences Legal Action Against David Dodd and Philip Theodore, Aeterna Alleges That Former CEO Dodd And Former General Counsel Theodore Breached Fiduciary Duties Owed To Company; Developed Secret Plans To Acquire U.S. Rights To Macrilen

Financial news for AEZS dated on 2017-07-26: Wall Street's M&A Chatter From July 25: Aeterna Zentaris, Rent-A-Center, Michael Kors-Jimmy Choo

Financial news for AEZS dated on 2017-07-25: AeternaZentaris Shares Spike ~\$0.10 Over Last Min. As Traders Circulate NY Post Article 'Longtime hockey exec rebrands himself as activist investor'; BZ NOTE: La Presse Article Earlier (7 a.m. EDT) Highlighted Same Story

Financial news for AEZS dated on 2017-07-25: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AEZS dated on 2017-07-24: 12 Biggest Mid-Day Losers For Monday

Financial news for AEZS dated on 2017-07-21: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for AEZS dated on 2017-07-21: Aeterna Zentaris +17% Premarket @\$3.28

Financial news for AEZS dated on 2017-07-20: Aeterna Zentaris Names Michael Ward CEO, David Dodd 'Ceased To Be' CEO With Immediate Effect; Co. Also Announces Formation Of Special 'Strategic Review Committee'

Financial news for AEZS dated on 2017-07-20: Mid-Afternoon Market Update: MarineMax Drops Following Q3 Results; Sarepta Shares Spike Higher

Financial news for AEZS dated on 2017-07-20: 15 Biggest Mid-Day Gainers For Thursday

Financial news for AEZS dated on 2017-07-20: Aeterna Zentaris Spikes to High of \$3.25

Financial news for AEZS dated on 2017-07-20: 28 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2017-07-19: Mid-Afternoon Market Update: Scripps Rises On Report Of Merger Talks With Discovery; DryShips Shares Slide

Financial news for AEZS dated on 2017-07-19: Aeterna Zentaris Inc. Up 124% On Day, Hearing Maxim Raised Price Target On Co. From \$2 To \$4

Financial news for AEZS dated on 2017-07-19: 18 Biggest Mid-Day Gainers For Wednesday

Financial news for AEZS dated on 2017-07-19: Mid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet

Financial news for AEZS dated on 2017-07-19: Mid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates

Financial news for AEZS dated on 2017-07-19: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEZS dated on 2017-07-18: Aeterna Zentaris Reports NDA For Macrilen For Evaluation Of Growth Hormone Deficiency In Adults Granted Dec. 30, 2017 PDUFA Date

Financial news for AEZS dated on 2017-06-30: Aeterna Zentaris Reports Resubmission Of NDA For Macrilen

Financial news for AEZS dated on 2017-05-18: Marcum Conference To Connect Public, Private Micro-Caps With Critical Investors

Financial news for AEZS dated on 2017-05-08: Aeterna Zentaris Reports Q1 EPS \$(0.31) vs \$(0.30) Est., Sales \$261K vs \$900K Est.

Financial news for AEZS dated on 2017-05-01: Mid-Afternoon Market Update: NASDAQ Up 50 Points; Ocwen Financial Shares Spike Higher

Financial news for AEZS dated on 2017-05-01: 15 Biggest Mid-Day Losers For Monday

Financial news for AEZS dated on 2017-05-01: Mid-Day Market Update: Crude Oil Down 1.5%; Neurotrope Shares Plummet

Financial news for AEZS dated on 2017-05-01: Mid-Morning Market Update: Markets Mostly Higher; DISH Network Profit Tops Estimates

Financial news for AEZS dated on 2017-05-01: Adam Feuerstein Tweets: \$AEZS -- Zoptrex mOS 10.9 months vs doxorubicin mOS 10.8 months. This is what happens when you compare doxorubicin to doxorubicin. Duh.

Financial news for AEZS dated on 2017-05-01: Aeterna Zentaris Shares to Resume Trade at 8:30 a.m. EDT

Financial news for AEZS dated on 2017-05-01: Aeterna Zentaris Phase 3 Zoptec Study Did Not Achieve Primary Endpoint

Financial news for AEZS dated on 2017-05-01: Aeterna Zentaris Shares Halted News Pending, Ahead of Data

Financial news for AEZS dated on 2017-04-28: Aeterna Zentaris Will Announce Top-Line Results Of ZoptEC Phase 3 Study May 1 Before Market Open

Financial news for AEZS dated on 2017-04-28: Aeterna Zentaris Announces Replacement at the Market Issuance Program with H.C. Wainwright

Financial news for AEZS dated on 2017-04-27: Adam Feuerstein Tweets: I'm told \$AEZS moved the goal line. Very well...

Financial news for AEZS dated on 2017-04-27: Adam Feuerstein Tweets: I forgot about \$AEZS. Zoptrex ph3 results expected end of April, so by tomorrow. Another doxorubicin reformulation a la \$CYTR. Uh oh...

Financial news for AEZS dated on 2017-03-30: 15 Biggest Mid-Day Gainers For Thursday

Financial news for AEZS dated on 2017-03-30: 20 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2017-03-30: Aeterna Zentaris Intends to File NDA with Respect to Macrilen In Q3

Financial news for AEZS dated on 2017-03-28: Aeterna Zentaris Reports ATM Issuance Program for \$9M in Shares, Can Sell Up to 3M Shares

Financial news for AEZS dated on 2017-03-21: F-3 from Aeterna Zentaris Shows Registration for \$50M Common Stock Offering

Financial news for AEZS dated on 2017-03-07: Aeterna Zentaris Reports EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen, Agrees That Co. May Defer Conducting Pediatric Investigation Plan Until After It Files A Marketing Authorization Application

Financial news for AEZS dated on 2017-02-15: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEZS dated on 2017-02-13: Aeterna Zentaris Reports Plans to Pursue FDA Registration of Macrilen

Financial news for AEZS dated on 2017-01-31: 15 Biggest Mid-Day Gainers For Tuesday

Financial news for AEZS dated on 2017-01-31: Mid-Day Market Update: Dow Falls Over 100 Points; DryShips Shares Spike Higher

Financial news for AEZS dated on 2017-01-31: Mid-Morning Market Update: Markets Open Lower; Mastercard Earnings Beat Views

Financial news for AEZS dated on 2017-01-31: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AEZS dated on 2017-01-18: 18 Stocks Moving In Wednesday's Pre-Market Session

Financial news for AEZS dated on 2017-01-05: Mid-Afternoon Market Update: CEB Surges On Acquisition News; Macy's Shares Slide

Financial news for AEZS dated on 2017-01-05: 18 Biggest Mid-Day Losers For Thursday

Financial news for AEZS dated on 2017-01-05: Mid-Day Market Update: Dow Falls Over 100 Points; Kohl's Shares Plummet

Financial news for AEZS dated on 2017-01-05: Mid-Morning Market Update: Markets Mixed; Walgreens Sales Miss Estimates

Financial news for AEZS dated on 2017-01-05: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for AEZS dated on 2017-01-04: Aeterna Zentaris Shares Down 47.95% After Resuming Trade At 5:46pm

Financial news for AEZS dated on 2017-01-04: Aeterna Zentaris Macrilen Failed To Achieve Its Objective In Phase 3 Trial, Company Evaluating Whether It Will Continue Development

Financial news for AEZS dated on 2017-01-04: Aeterna Zentaris Offers Results of Confirmatory Phase 3 Trial of Macrilen

Financial news for AEZS dated on 2017-01-04: Aeterna Zentaris Shares Halted News Pending

Financial news for AEZS dated on 2016-11-08: Aeterna Zentaris Reports Q3 EPS \$(0.61) vs. Est. \$(0.73), Rev. \$269K vs. Est. \$160K

Financial news for AEZS dated on 2016-10-14: 18 Stocks Moving In Friday's Pre-Market Session

Financial news for AEZS dated on 2016-10-13: 10 Biggest Mid-Day Gainers For Thursday

Financial news for AEZS dated on 2016-10-12: Aeterna Zentaris Reports Exclusive License Deal with Specialised Therapeutics Asia for Potential Marketing of Zoptrex in Australia, New Zealand

Financial news for AEZS dated on 2016-08-09: Aeterna Zentaris Reports Q2 EPS \$(0.71) vs \$(0.82) Est., Sales \$96K vs \$750K Est.

Financial news for AEZS dated on 2016-08-01: Aeterna Zentaris and Rafa Laboratories Sign Exclusive License Agreement for Zoptrex in Israel

Financial news for AEZS dated on 2016-07-01: Mid-Afternoon Market Update: IntriCon Drops On Weak Forecast; Thor Industries Shares Spike Higher

Financial news for AEZS dated on 2016-07-01: 12 Biggest Mid-Day Gainers For Friday

Financial news for AEZS dated on 2016-07-01: Mid-Day Market Update: Franklin Covey Slides Following Weak Results; Aeterna Zentaris Shares Surge

Financial news for AEZS dated on 2016-07-01: Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs

Financial news for AEZS dated on 2016-07-01: Aeterna Zentaris, Orient EuroPharma Co., Ltd. Sign Exclusive License Agreement for Zoptrex in Taiwan and Southeast Asia

Financial news for AEZS dated on 2016-06-14: Aeterna Zentaris Announces Submission Of Investigational New Drug Application

Financial news for AEZS dated on 2016-06-06: Aeterna Zentaris Says Pivotal Phase III Trial for Endometrial Cancer Expected to be Closed in Q3'16

Financial news for AEZS dated on 2016-05-09: Aeterna Zentaris Reports Q1 EPS \$(0.37) May Not Compare to \$(0.74) Est.

Financial news for AEZS dated on 2016-04-27: Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY Prostate Cancer Blood Test

Financial news for AEZS dated on 2016-03-29: Aeterna Zentaris Reports Q4 EPS \$(1.46) vs. Est. \$(1.30)

Financial news for AEZS dated on 2016-03-01: Aeterna Zentaris Reports Development Progress of Zoptrex in China: Clinical Development Expected to Start in '16

Financial news for AEZS dated on 2016-02-23: Aeterna Zentaris Starts Promotional Activities for APIFINY Prostate Cancer Blood Test

Financial news for AEZS dated on 2016-02-18: Aeterna Zentaris Names Genevieve Lemaire Chief Accounting Officer

Financial news for AEZS dated on 2016-01-25: Aeterna Zentaris Surged 17%: Here Is What You Need To Know

Financial news for AEZS dated on 2016-01-25: Aeterna Zentaris Spike to High of \$3.60, +17.5%; Co Announced Stock Purchases by Management

Financial news for AEZS dated on 2016-01-25: Aeterna Zentaris PR Highlights Recent Management Stock Purchases

Financial news for AEZS dated on 2016-01-19: Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Views

Financial news for AEZS dated on 2016-01-19: Aeterna Zentaris +24.34% Premarket @\$3.32; Co Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen

Financial news for AEZS dated on 2016-01-19: Aeterna Zentaris Finishes Meeting With Clinical Investigators For Phase 3 Trial Of Macrilen

Financial news for AEZS dated on 2016-01-13: UPDATE: Aeterna Zentaris Says in Early Stages of Developing Compounds Based on Another Cytotoxic Agent Which Would Follow Zoptrex

Financial news for AEZS dated on 2016-01-13: UPDATE: Aeterna Zentaris Syas Offered Update on Progress of Zoptrex: Recently Received DSMB Recommendation to Continue ZoptEC Phase 3 Trial

Financial news for AEZS dated on 2016-01-13: Aeterna Zentaris Release Shows Affirmation of Focus on Targeted Oncology at JP Morgan Healthcare Conference

Financial news for AEZS dated on 2015-12-30: UPDATE: Aeterna Zentaris Prospectus Allows for Co. to Offer Up to \$150M in Mixed Securities

Financial news for AEZS dated on 2015-12-30: Aeterna Zentaris Reports Filing of Prelim. Base Shelf Prospectus

Financial news for AEZS dated on 2015-12-17: 13G Filing from Sabby Mgmt on Aeterna Zentaris Shows New 7.05% Stake

Financial news for AEZS dated on 2015-12-09: Benzinga's Top #PreMarket Losers

Financial news for AEZS dated on 2015-12-09: Aeterna Zentaris Prices Offering of Common Shares, Warrants at \$5.55/Share Plus Warrant to Purchase 0.7 Common Shares

Financial news for AEZS dated on 2015-12-08: Aeterna Zentaris Reports Proposed Offering Of Stock, Warrants; Details Not Disclosed

Financial news for AEZS dated on 2015-12-08: Aeterna Zentaris Regains NASDAQ \$1/Share Minimum Compliance, Reports FY16 Corp. Objectives

Financial news for AEZS dated on 2015-12-02: HC Wainwright Reiterates Buy, Raises Target from \$11 to \$12 on Aeterna Zentaris, Highlights 'Building an Oncology Franchise Ahead of Zoptrex'

Financial news for AEZS dated on 2015-12-01: Benzinga's Volume Movers

Financial news for AEZS dated on 2015-12-01: Aeterna Zentaris, Armune BioScience Finish Co-Marketing Agreement for APIFINY Prostate Cancer Blood Test

Financial news for AEZS dated on 2015-11-30: Morning Market Losers

Financial news for AEZS dated on 2015-11-30: Benzinga's Top #PreMarket Losers

Financial news for AEZS dated on 2015-11-30: UPDATE: Shkreli Says Aeterna Zentaris, Cyclacel, MacroCure Worthless

Financial news for AEZS dated on 2015-11-27: Aeterna Zentaris Spikes Higher

Financial news for AEZS dated on 2015-11-27: Morning Market Losers

Financial news for AEZS dated on 2015-11-27: Benzinga's Top #PreMarket Gainers

Financial news for AEZS dated on 2015-11-27: Aeterna Zentaris +9% Premarket @\$12.43

Financial news for AEZS dated on 2015-11-25: UPDATE: Aeterna Zentaris Affirms Business, Prospects Remain Fundamentally Strong

Financial news for AEZS dated on 2015-11-25: Aeterna Zentaris Affirms Fundamental Strength Of Business

Financial news for AEZS dated on 2015-11-24: Aeterna Zentaris Shares Selling Following PR Confirming No Corporate Developments

Financial news for AEZS dated on 2015-11-24: Aeterna Zentaris PR Confirms No Corporate Developments

Financial news for AEZS dated on 2015-11-24: Benzinga's Volume Movers

Financial news for AEZS dated on 2015-11-24: Morning Market Gainers

Financial news for AEZS dated on 2015-11-24: Benzinga's Top #PreMarket Gainers

Financial news for AEZS dated on 2015-11-24: Aeterna Zentaris +45% Premarket @\$12.35

Financial news for AEZS dated on 2015-11-23: Aeterna Zentaris Senior VP Phil Theodore Tells Benzinga There is No News That Can be Discussed With Analyst or Media; Says Stay Tuned for Public Information

Financial news for AEZS dated on 2015-11-23: Aeterna Zentaris +30% After-Hours @\$9.80

Financial news for AEZS dated on 2015-11-23: Aeterna Zentaris +91% @\$8.09

Financial news for AEZS dated on 2015-11-19: Aeterna Zentaris Reports First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen for AGHD

Financial news for AEZS dated on 2015-11-18: Aeterna Zentaris Offers Details of Steps to Regain NASDAQ Compliance

Financial news for AEZS dated on 2015-11-05: Aeterna Zentaris Reports Q3 \$(0.07) vs. Est. \$(0.06)

Financial news for AEZS dated on 2015-11-03: Aeterna Zentaris Shares Fall Quickly

Financial news for AEZS dated on 2015-11-02: Aeterna Zentaris Reports Agreement to Exercise Substantially All Remaining Series B Warrants

Financial news for AEZS dated on 2015-10-27: Leading Independent Advisory Firms ISS and Glass Lewis Recommend Shareholders of Aeterna Zentaris Vote FOR Share Consolidation

Financial news for AEZS dated on 2015-10-16: Aeterna Zentaris Reports Special Meeting of Shareholders and Mailing of Management Information Circular

Financial news for AEZS dated on 2015-10-13: Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer

Financial news for AEZS dated on 2015-09-28: Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration, Taxane Resistant Prostate Cancer

Financial news for AEZS dated on 2015-09-21: Aeterna Zentaris Fall 25% Premarket Following Announcement of Amendment to Series B Warrants

Financial news for AEZS dated on 2015-09-21: Aeterna Zentaris Announces Amendment to Series B Warrants, Enters Definitive Agreement With ~90% Of Outstanding Series B Holders

Financial news for AEZS dated on 2015-09-08: Stocks Hitting 52-Week Lows

Financial news for AEZS dated on 2015-08-13: Aeterna Zentaris Reports Q2 EPS \$(0.14) vs. Est. \$(0.08)

Financial news for AEZS dated on 2015-08-11: Aeterna Zentaris Reports Data, Safety Monitoring Board Scheduled to Close Second Interim Analysis of ZoptEC Phase 3 Trial in Early October

Financial news for AEZS dated on 2015-08-11: Aeterna Zentaris Reports Data, Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October

Financial news for AEZS dated on 2015-07-28: Aeterna Zentaris Grants Option to Develop, Commercialize Oral Allogenic Cancer Vaccine Technology

Financial news for AEZS dated on 2015-07-27: Aeterna Zentaris Begins Promotional Activities for EMD Serono's Saizen [Somatropin for Injection]

Financial news for AEZS dated on 2015-06-30: Aeterna Zentaris Finishes Patient Recruitment for ZoptEC Phase 3 Study with Zoptarelin Doxorubicin in Advanced Endometrial Cancer

Financial news for AEZS dated on 2015-06-25: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD

Financial news for AEZS dated on 2015-06-18: Aeterna Zentaris Reports Extension to Regain NASDAQ Compliance for Minimum Bid Price Rule

Financial news for AEZS dated on 2015-05-26: Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen in AGHD Meets EMA's Study-Design Expectations

Financial news for AEZS dated on 2015-04-14: HC Wainwright Upgrades AEterna Zentaris to Buy, Announces \$1.25 PT

Financial news for AEZS dated on 2015-04-13: Aeterna Zentaris Reports Plans to Start Phase 3 Study of Macrilen(tm) in AGHD After Successful Meeting with FDA

Financial news for AEZS dated on 2015-03-31: Aeterna Zentaris Transfers Agreement of its Discovery Library with the Medical University of South Carolina

Financial news for AEZS dated on 2015-03-17: Earnings Scheduled For March 17, 2015

Financial news for AEZS dated on 2014-12-29: Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

Financial news for AEZS dated on 2014-12-19: Aeterna Zentaris Announces Receiving Notification from NASDAQ Related to Minimum Bid Price

Financial news for AEZS dated on 2014-12-01: Aeterna Zentaris, Sinopharm A-Think Report Signing of Master Collaboration Deal for Zoptarelin Doxorubicin in China

Financial news for AEZS dated on 2014-11-20: Aeterna Zentaris Adds Hollings Cancer Center To Multi-National Phase 3 Trial In Endometrial Cancer

Financial news for AEZS dated on 2014-11-06: Morning Market Losers

Financial news for AEZS dated on 2014-11-06: PREVIEW: Aeterna Zentaris to Resume Trading at 7:30 AM ET

Financial news for AEZS dated on 2014-11-06: Aeterna Zentaris Inc Announces It Has Received Complete Response Letter From FDA For Macrilen

Financial news for AEZS dated on 2014-11-05: UPDATE: Aeterna Zentaris Halt Likely Related to PDUFA Date for Macrilen

Financial news for AEZS dated on 2014-11-05: Shares of Aeterna Zentaris Halted News Pending

Financial news for AEZS dated on 2014-11-04: AEterna Zentaris Inc. Reports Q3 EPS of \$(0.20) vs \$(0.16) Est

Financial news for AEZS dated on 2014-08-07: AEterna Zentaris Inc. Reports Q2 EPS of

\$(-0.09) vs \$(-0.19) Est; Revenue of \$0.00, Down 100% YOY

Financial news for AEZS dated on 2014-07-17: UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris

Financial news for AEZS dated on 2014-07-17: HC Wainwright Initiates Coverage on AEterna Zentaris Inc. at Buy, Announces \$3.00 PT

Financial news for AEZS dated on 2014-05-12: UPDATES: Aeterna Zentaris Names David Dodd as Chair, Says May Sell Up to 14M Shares for Up to \$15M

Financial news for AEZS dated on 2014-05-12: Aeterna Zentaris Names David Dodd as Chair, Says May Sell Up to 14M Shares for Up to \$15M

Financial news for AEZS dated on 2014-03-20: Aeterna Zentaris Reports Q4 Loss from Continuing Operations \$0.28/Share

Financial news for AEZS dated on 2014-03-20: AEterna Zentaris Inc. Reports Q4 EPS of \$(-0.22) vs \$(-0.04) Est

Financial news for AEZS dated on 2014-01-09: Morning Market Losers

Financial news for AEZS dated on 2014-01-08: Aeterna Zentaris Announces Proposed Unit Offering; Pricing, Number of Units to be Determined

Financial news for AEZS dated on 2014-01-06: Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by FDA

Financial news for AEZS dated on 2014-01-03: Aeterna Zentaris Names Dr. Richard Sachse as Chief Scientific Officer

Financial news for AEZS dated on 2013-12-12: Seeking Alpha: ' Aeterna Zentaris: Mispriced \$1 Biotech Stock With Limited Downside Risk And Big Upside Potential'

Financial news for AEZS dated on 2013-11-20: Stocks Hitting 52-Week Lows

Financial news for AEZS dated on 2013-11-20: Morning Market Losers

Financial news for AEZS dated on 2013-11-20: Aeterna Zentaris Prices 13.1M Unit Offering at \$1.15/Unit

Financial news for AEZS dated on 2013-10-01: Aeterna Zentaris Closes Transfer of Cetrotide Rights to Merck

Financial news for AEZS dated on 2013-08-28: Aeterna Zentaris Reports Listing Transfer to NASDAQ Capital Market

Financial news for AEZS dated on 2013-08-08: AEterna Zentaris Inc. Reports Q2 EPS of \$0.37, Up 54% YOY; Revenue of \$30.10M, Up 303% YOY

Financial news for AEZS dated on 2013-07-25: Stocks Hitting 52-Week Lows

Financial news for AEZS dated on 2013-07-25: Aeterna Zentaris to Sell 5.2M Shares at \$1.50/Share

Financial news for AEZS dated on 2013-07-25: Euro Pacific Initiates Coverage on AEterna Zentaris Inc. at Hold

Financial news for AEZS dated on 2013-05-08: Aeterna Zentaris Announces Election of Directors at its Annual Meeting of Shareholders

Financial news for AEZS dated on 2013-05-07: AEterna Zentaris Inc. Reports Q1 EPS of \$(-0.07) vs \$(-0.29) Est; Revenue of \$16.60M vs \$8.34M Est

Financial news for AEZS dated on 2013-04-17: Aeterna Zentaris to Transfer Manufacturing Rights for Cetrotide to Merck

Financial news for AEZS dated on 2013-04-15: Aeterna Zentaris Names David Dodd Pres, CEO

Financial news for AEZS dated on 2013-04-10: Aeterna Zentaris Issues Encouraging Updated Data on LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates

Financial news for AEZS dated on 2013-03-21: AEterna Zentaris Inc. Reports Q4 EPS of \$(-0.29) vs \$(-0.31) Est; Revenue of \$9.55M vs \$7.96M Est

Financial news for AEZS dated on 2013-03-21: Earnings Scheduled For March 21, 2013

Financial news for AEZS dated on 2013-03-11: Aeterna Zentaris Shares Resume Trading,

Now Down 8%

Financial news for AEZS dated on 2013-03-11: Shares of Aeterna Zentaris to Resume Trade at 11:45AM EST

Financial news for AEZS dated on 2013-03-11: UPDATE: Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with Perifosine

Financial news for AEZS dated on 2013-03-11: Aeterna Zentaris to Discontinue Phase 3 Trial in Multiple Myeloma with perifosine Amid Data Safety Monitoring Board Recommendation

Financial news for AEZS dated on 2013-03-11: Aeterna Zentaris Halted News Pending

Financial news for AEZS dated on 2013-01-03: McNicoll Lewis Vlak Upgrades AEterna Zentaris Inc. to Buy

Financial news for AEZS dated on 2012-12-31: UPDATE: Canaccord Genuity Reiterates Hold Rating, Raises PT on AEterna Zentaris

Financial news for AEZS dated on 2012-12-31: Canaccord Genuity Maintains Hold on AEterna Zentaris Inc., Raises PT to \$2.50

Financial news for AEZS dated on 2012-12-28: Mid-Day Market Movers

Financial news for AEZS dated on 2012-12-28: Benzinga's Top Pre-Market Gainers

Financial news for AEZS dated on 2012-12-28: Aeterna Zentaris Wins FDA Special Protocol Assessment for Phase 3 Registration Trial in Endometrial Cancer with AEZS-108

Financial news for AEZS dated on 2012-12-28: Aeterna Zentaris Granted SPA by FDA for Phase 3 AEZS-108 Registration Trial in Endometrial Cancer

Financial news for AEZS dated on 2012-12-11: Benzinga's Top Pre-Market Gainers

Financial news for AEZS dated on 2012-12-11: Aeterna Zentaris: Final Phase 2 Data Demonstrate Perifosine and Sorafenib Combination Therapy Well Tolerated by Heavily Pretreated Lymphoma Patients

Financial news for AEZS dated on 2012-11-26: Aeterna Zentaris Announces Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting

Financial news for AEZS dated on 2012-11-13: Aeterna Zentaris Reports Q3 EPS \$-0.35 vs \$-0.43 Est; Revenues \$7.1M vs \$8.38M Est

Financial news for AEZS dated on 2012-11-08: Aeterna Zentaris Presents Promising Results for Disorazol Z Cytotoxic Conjugates

Financial news for AEZS dated on 2012-10-22: Stocks Hitting 52-Week Lows

Financial news for AEZS dated on 2012-10-22: Aeterna Zentaris Regains Compliance with NASDAQ \$1.00 Minimum Bid Price Rule

Financial news for AEZS dated on 2012-10-17: Aeterna Zentaris Announces Closing of \$16.5 Million Public Offering of Common Shares and Warrants

Financial news for AEZS dated on 2012-10-17: FDA Considering Faster Pathway for Treatments of Deadly or Debilitating Diseases

Financial news for AEZS dated on 2012-10-12: Bloom Burton & Co. Maintains Aeterna Zentaris at Sell, Lowers PT from \$2.25 to \$2

Financial news for AEZS dated on 2012-10-12: Aeterna Zentaris Announces Pricing of US \$16.5 Million Public Offering of Common Shares and Warrants

Financial news for AEZS dated on 2012-10-12: Benzinga's Top Pre-Market Losers

Financial news for AEZS dated on 2012-10-11: Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

Financial news for AEZS dated on 2012-09-25: Aeterna Zentaris Granted Patent by European Patent Office for AEZS-130

Financial news for AEZS dated on 2012-09-20: Benzinga's Microcap Movers for Thursday September 20, 2012

Financial news for AEZS dated on 2012-08-24: Aeterna Zentaris Spikes Higher

Financial news for AEZS dated on 2012-08-14: Benzinga's Microcap Movers for Monday August 14, 2012

Financial news for AEZS dated on 2012-08-14: Aeterna Zentaris Reports Q2 EPS \$0.04 vs \$-0.06 Est

Financial news for AEZS dated on 2012-08-07: Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

Financial news for AEZS dated on 2012-07-24: Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

Financial news for AEZS dated on 2012-06-28: Aeterna Zentaris and Partner Yakult Initiates Phase 1 Trial in Multiple Myeloma with Perifosine in Japan

Financial news for AEZS dated on 2012-06-26: Benzinga's Microcap Movers for Tuesday June 26, 2012

Financial news for AEZS dated on 2012-06-26: Aeterna Zentaris Announces Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting

Financial news for AEZS dated on 2012-06-21: Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma

Financial news for AEZS dated on 2012-06-19: Aeterna Zentaris Learns of Class Action Lawsuits Filed and Denies Allegations

Financial news for AEZS dated on 2012-06-05: Aeterna Zentaris Announces Phase 1 Data for Perifosine in Multiple Myeloma Published in the British Journal of Haematology

Financial news for AEZS dated on 2012-05-16: Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price

Financial news for AEZS dated on 2012-05-07: Aeterna Zentaris Regains North American Rights for Perifosine from Keryx

Financial news for AEZS dated on 2012-05-07: Aeterna Zentaris Regains North American Rights for Perifosine from Keryx

Financial news for AEZS dated on 2012-04-02: Oppenheimer Downgrades Aeterna Zentaris from Outperform to Perform, Removes PT

Financial news for AEZS dated on 2012-04-02: Morning Market Losers

Financial news for AEZS dated on 2012-04-02: Keryx Biopharmaceuticals Falls 58% on Failed Phase 3 Results

Financial news for AEZS dated on 2012-04-02: Keryx Biopharmaceuticals, Aeterna Zentaris Resume Trading

Financial news for AEZS dated on 2012-04-02: A Peek Into The Market Before The Trading Starts

Financial news for AEZS dated on 2012-04-02: PREVIEW: Keryx Biopharmaceuticals, Aeterna Zentaris to Resume Trading at 7:30am

Financial news for AEZS dated on 2012-04-02: Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer; Did not Meet Primary Endpoint

Financial news for AEZS dated on 2012-03-27: Aeterna Zentaris Reports Q4 \$(0.07) vs \$(0.09) Est; Revs \$12.6M vs \$7.78M Est

Financial news for AEZS dated on 2012-03-08: Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial in Cancer Cachexia with Aeterna Zentaris' Ghrelin Agonist, AEZS-130

Financial news for AEZS dated on 2012-03-06: Keryx Biopharma Trade Lower after Adam Feuerstein's Negative Blog Post

Financial news for AEZS dated on 2012-03-05: Aeterna Zentaris Trading 17.7% Higher on Heavy Volume; Currently at \$2.06

Financial news for AEZS dated on 2012-02-03: Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer; Demonstrated Early Evidence of Antitumor Activity

Financial news for AEZS dated on 2012-01-31: Aeterna Zentaris Spiking Higher

Financial news for AEZS dated on 2012-01-26: Scorecard and New Picks: Technical Value Fishing Under \$5

Financial news for AEZS dated on 2012-01-24: Oppenheimer Reduces AEterna Zentaris PT

Financial news for AEZS dated on 2012-01-24: Aeterna Zentaris Announces "At-the-Market" Issuance Program of up to \$16M

Financial news for AEZS dated on 2012-01-05: Aeterna Zentaris Announces Collaboration with Ventana Medical Systems to Develop Companion Diagnostic in Cancer for AEZS-108

Financial news for AEZS dated on 2012-01-03: Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan

Financial news for AEZS dated on 2011-12-13: Aeterna Zentaris Announces Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting

Financial news for AEZS dated on 2011-12-12: Aeterna Zentaris Announces Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting

Financial news for AEZS dated on 2011-12-09: Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131,

Financial news for AEZS dated on 2011-11-28: Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia

Financial news for AEZS dated on 2011-11-23: Financial Breakfast: Morning News Summary for November 23, 2011

Financial news for AEZS dated on 2011-11-23: Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa Region

Financial news for AEZS dated on 2011-11-16: Aeterna Zentaris Presents Encouraging Preclinical Data for Disorazol Z at AACR-NCI-EORTC Conference

Financial news for AEZS dated on 2011-11-14: Rodman & Renshaw Reiterates Outperform, \$3 PT on Aeterna Zentaris

Financial news for AEZS dated on 2011-11-10: Oppenheimer Outperform on AEterna Zentaris

Financial news for AEZS dated on 2011-10-27: Aeterna Zentaris Chatter from Seeking Alpha Post

Financial news for AEZS dated on 2011-10-27: Aeterna Zentaris Spiking Higher on Takeover Chatter

Financial news for AEZS dated on 2011-10-25: Aeterna Zentaris: FDA Grants IND to Investigator at University of Miami School of Medicine for Phase 2 Trial with AEZS-108 in Triple-Negative Breast Cancer

Financial news for AEZS dated on 2011-10-13: Keryx Biopharmaceuticals Announces Phase 1 / 2 Clinical Trial Results of KRX-0401 Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma Published in the Journal of Clinical Oncology

Financial news for AEZS dated on 2011-10-05: Aeterna Zentaris: Journal of Clinical Oncology Publishes Phase 2 Clinical Trial Results of Perifosine Plus Capecitabine in Patients with Metastatic Colorectal Cancer

Financial news for AEZS dated on 2011-09-26: Aeterna Zentaris Announces Interim Data for its Phase 1/2 Trial with AEZS-108 in Prostate Cancer at ESMO Congress; AEZS-108 well tolerated at all dose levels / Early evidence of anti-tumor activity

Financial news for AEZS dated on 2011-09-15: Rodman & Renshaw Outperform on AEterna Zentaris

Financial news for AEZS dated on 2011-09-01: Rodman & Renshaw Reiterates Aeterna Zentaris Market Outperform, \$3 PT

Financial news for AEZS dated on 2011-08-31: Aeterna Zentaris Announces Completion of Interim Analysis by Data Safety Monitoring Board for the Phase 3 Study of Perifosine for the Treatment of Refractory Advanced Colorectal Cancer

Financial news for AEZS dated on 2011-08-30: McNicoll, Lewis & Vlasko Maintains Aeterna Zentaris Buy, PT

Financial news for AEZS dated on 2011-08-30: Aeterna Zentaris Announces Favorable Top-Line Results of Completed Phase 3 Study on AEZS-130

Financial news for AEZS dated on 2011-08-30: Aeterna Zentaris Announces Results of its Novel Orally Active Anticancer Erk Inhibitor at the American Chemical Society National Meeting

Financial news for AEZS dated on 2011-08-09: Desjardins Upgrades AEterna Zentaris to Buy From Hold

Financial news for AEZS dated on 2011-08-09: Desjardins Upgrades AEZS To Buy

Financial news for AEZS dated on 2011-07-27: Aeterna Zentaris Announces Completion of Patient Recruitment for Phase 3 Trial with Perifosine in Refractory Advanced Colorectal Cancer

Financial news for AEZS dated on 2011-07-26: Aeterna Zentaris Completes Phase 3 Study on AEZS-130 as First Oral Diagnostic Test for Adult Growth Hormone Deficiency

Financial news for AEZS dated on 2011-07-20: Aeterna Zentaris Successfully Reached a Key Milestone in the Non-Clinical Development of its Oral Prostate Cancer Vaccine Candidate, AEZS-120

Financial news for AEZS dated on 2011-07-18: Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming ESGO Meeting

Financial news for AEZS dated on 2011-07-12: A Peek Into The Market Before The Trading Starts

Financial news for AEZS dated on 2011-07-12: Aeterna Zentaris Granted Patent for Perifosine by European Patent Office

Financial news for AEZS dated on 2011-06-29: Aeterna Zentaris Announces "At-the-Market" Issuance Program to Sell up 9.5M Shares

Financial news for AEZS dated on 2011-06-07: Oppenheimer Initiates AEterna Zentaris At Outperform, \$5.50 PT

Financial news for AEZS dated on 2011-04-05: Aeterna Zentaris Announces Results on AEZS-131, a Highly Selective Erk 1/2 Inhibitor Anticancer Compound at American Association for Cancer Research Annual Meeting

Financial news for AEZS dated on 2011-04-04: Aeterna Zentaris Announces Results On Its Lead Anticancer Agent Perifosine at American Association for Cancer Research Annual Meeting

Financial news for AEZS dated on 2011-03-24: Aeterna Zentaris Awarded Grant by German Government to Develop Novel Targeted Anti-Cancer Compounds

Financial news for AEZS dated on 2011-03-22: Aeterna Zentaris Reports Q4 EPS of \$(0.03) vs. \$(0.07)

Financial news for AEZS dated on 2010-12-20: A Peek Into The Market Before The Trading Starts

Financial news for AEZS dated on 2010-12-20: Aeterna Zentaris Receives Agreement from FDA on Special Protocol Assessment for Solorel

Financial news for AEZS dated on 2010-11-10: Aeterna Zentaris to Present Phase 2 Results for AEZS-108 at Major Conference

Financial news for AEZS dated on 2010-11-09: Aeterna Zentaris Reports Third Quarter EPS of \$(0.12)

Financial news for AEZS dated on 2010-10-05: Aeterna Zentaris Announces Orphan Drug AEZS-130 Interim Phase 3 Data Analysis Shows Potential for 2011 Filing

Financial news for AEZS dated on 2010-05-17: Top Day Trader Alerts (AEZS, AMSC, APCVZ, DBTK, HAUP, LOW, HD, OSIP, SIRI, TIVO)

Financial news for AEZS dated on 2010-05-17: Benzinga's Top Pre-Market Gainers (NLST, AEZS, SCLN, BPAX, TIVO)

Financial news for AEZS dated on 2010-05-17: Top Analyst Upgrades and Downgrades (AEZS, ACV, MDRX, CAAS, DELL, HPQ, BEE, SIMG, SY, TEF, TIVO, WCRX)

Financial news for AEZS dated on 2010-05-13: AEterna (AEZS) Pares Down Its Losses

Financial news for AEZS dated on 2010-05-12: Market Roundup (IBM, SBUX, MCD, AEZS, MBLX)

Financial news for AEZS dated on 2010-05-12: Benzinga's Top Pre-Market Gainers (SMTX, NLST, ACHN, AEZS, VICL)

Financial news for AEZS dated on 2010-04-06: Keryx Drug Is On "Fast-Track" (KERX, AEZS)

Financial news for AEZS dated on 2010-04-05: Market Roundup (KERX, AEZS, PEP, BUD, GOOG, BRK.A, FRE, ZION, RF, MTB)

Financial news for AEZS dated on 2010-03-24: Benzinga's Top Pre-Market Gainers (AEZS, ADBE, MF, NVAX)

Financial news for AEZS dated on 2009-12-10: Aeterna Zentaris Inc. (AEZS) Going Strong

Financial news for AEZS dated on 2009-09-16: Today's Morning Top Gainers (SPEX, KERX, ACAS, AEZS, DARA)